Diagnostics

A new law makes Illinois a pioneer, mandating Medicaid coverage for predictive blood tests. Can this tech-driven policy shift the tide on maternal health?

Dynacare's new at-home hormone tests promise unprecedented access and privacy. But are Canadians ready to navigate their health data outside the clinic?

Pathway Labs' FDA-cleared AI, EchoNext, detects hidden heart disease. A key partnership and $8.5M seed round signal a major shift for MedTech investors.

A new NYC startup, Yunara Life, is betting it can solve healthcare's engagement crisis by letting users earn aesthetic rewards for healthy habits. Is this a brilliant hack or a concerning trend?

An EY award for Rhythm Express founders highlights a deeper story of strategic innovation, patient-centric design, and the future of remote health monitoring.

A pivotal NCCN guideline update for bladder cancer validates Natera's Signatera test, ushering in a new era of personalized, MRD-guided cancer treatment.

Spotlight Medical's myStage Dx secures tough IVDR CE mark, using AI on standard lab slides to help doctors pinpoint which patients can safely avoid chemo.

The diagnostics firm is launching a monthly webinar series, an unusual move that blends investor relations with direct-to-consumer marketing. Is this the new playbook?

A $100k grant will help hospitals decide between local and send-out DNA testing for transplant monitoring, a move that could reshape patient care and markets.

Digital health innovator Light AI has secured C$5M to navigate the regulatory maze. Can its AI platform truly revolutionize diagnostics from our pockets?

For decades, insomnia treatment meant risky sedatives. Now, a new class of drugs is revolutionizing sleep science, promising safer rest for millions.

Kardium’s landmark FDA win and a new wave of innovators signal a biotech boom, cementing British Columbia's status as a global hub for health innovation.

A new study of 100M insurance claims reveals a shocking failure: nearly 9 in 10 women in some states get no osteoporosis care after a fracture. Why?

For years, CIDP patients faced limited options. Now, a wave of targeted therapies promises to transform treatment, sparking a multi-billion dollar market boom.

Utah's Co-Diagnostics is transferring its AI-powered diagnostic platform to a Saudi JV. It's a bold move to crack a booming market and a critical test of its strategy.

A new drug from Cambrian Bio shows promise in activating a key metabolic switch. This could lead to treatments that burn fat while preserving muscle mass.

A Taipei delegation at BIO 2026 signals Taiwan's strategic pivot from manufacturing to R&D, seeking global partners for its late-stage drugs and platforms.

At BIO 2026, Transpire Bio isn't just presenting; it's pitching a new paradigm for medicine, using inhalation to tackle everything from diabetes to cancer.

GSK and Spero Therapeutics have won FDA approval for Utebzi, the first oral carbapenem for complex UTIs, a move that could slash healthcare costs.

With $4.3M in seed funding and a roster of industry titans, Acurion is poised to commercialize its OncoGaze™ AI, aiming to make precision oncology faster.